Formulation and Evaluation of Transferosomes Loaded with an Anti-Hyperlipidemic Drug

The primary goal of this research is to create transferosome formulations that contain an anti-hyperlipidemic medication. Simvastatin, the medication employed in the formulation, has a low bioavailability of 60% and undergoes substantial hepatic degradation. These are the deformable nano-vesicles which can deliver both hydrophilic and hydrophobic drugs through transdermal route to enhance the Bioavailability of drugs which undergoes extensive hepatic metabolism when given through oral route which can increase patient compliance. Transferosomes are prepared and characterized by various evaluation tests like SEM analysis, vesicular size, surface morphology. After all evaluations done, Out of 12 formulations F2 formulation showed more entrapment efficiency. The reason for this is that there are more phospholipids present, and as the surfactant concentration rises, medication release becomes more rapid. Our main goal is to improve bioavailability, which can be accomplished by optimising the concentrations of phospholipid and surfactant in this drug delivery system, resulting in a controlled release of drug.